|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
00950 LEE'S PHARM
Nominal 
1.160 -0.005 (-0.429%) | 2026/06 - Interim HKD(K$) | %Chg (Compare to Interim) | 2025/12 HKD(K$) | 2024/12 HKD(K$) | 2023/12 HKD(K$) | 2022/12 HKD(K$) | |
| Turnover | 796,566 | 14.643% | 1,435,980 | 1,399,969 | 1,053,034 | 1,233,148 |
| Cost of Sales | (349,116) | 4.286% | (706,420) | (646,614) | (501,723) | (462,393) |
| Gross Profit | 447,450 | 24.273% | 729,560 | 753,355 | 551,311 | 770,755 |
| 2026/06 - Interim HKD(K$) | %Chg (Compare to Interim) | 2025/12 HKD(K$) | 2024/12 HKD(K$) | 2023/12 HKD(K$) | 2022/12 HKD(K$) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (1,391) | 185.041% | (1,847) | (839) | (870) | (1,104) | |
| Profit / (Loss) before Taxation | 86,461 | 42.499% | 72,886 | 98,113 | 30,785 | 67,861 | |
| Taxation | (23,599) | 132.984% | (22,270) | (29,501) | (10,836) | (22,026) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 32,152 | 93.233% | 41,322 | 24,487 | (3,251) | 5,449 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 95,014 | 41.421% | 91,938 | 93,099 | 16,698 | 51,284 | |
| 2026/06 - Interim HKD(K$) | %Chg (Compare to Interim) | 2025/12 HKD(K$) | 2024/12 HKD(K$) | 2023/12 HKD(K$) | 2022/12 HKD(K$) | |
| Net Finance Costs / (Income) | 4,713 | -9.678% | 9,444 | 12,057 | 10,364 | 5,202 |
| Depreciation & Amortisation | 96,638 | 33.940% | 155,650 | 147,731 | 149,501 | 152,499 |
| Directors' Emoluments | -- | -- | -- | 36,668 | 32,861 | 10,264 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | 16.140 | 41.455% | 15.610 | 15.810 | 2.840 | 8.710 |
| DPS (cts) | 3.500 | -- | 4.500 | 4.500 | 1.800 | 2.000 |
| Dividend Payout Ratio (%) | 21.685% | -- | 28.828% | 28.463% | 63.380% | 22.962% |
| Cash flow per share ($) | -- | -- | 0.565 | 0.411 | 0.187 | 0.482 |
| NBV per share ($) | 3.609 | -- | 3.474 | 2.805 | 3.463 | 3.268 |
| Remarks: | Real time quote last updated: 11/09/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K$) | HKD 95,014 |
| %Change | 41.421% |
| EPS / (LPS) | HKD 0.161 |
| NBV Per Share ($) | HKD 3.609 |